Crispr Therapeutics Ag (CRSP)

$46.24 -0.71 (-1.51%)
Market Cap 4.58B
Revenue (ttm) 3.51M
Net Income (ttm) -581.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -16,569.80%
Debt to Equity Ratio 0.00
Volume 2,561,300
Avg Vol 2,003,434
Day's Range N/A - N/A
Shares Out 95.99M
Stochastic %K 4%
Beta 1.72
Analysts Strong Sell
Price Target $80.46

Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therap...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 41 561 32 77
Address:
Baarerstrasse 14, Zug, Switzerland
DragonAlgo
DragonAlgo Mar. 21 at 12:01 AM
🐉 $CRSP PUT — DragonAlgo® Signal Contract: CRSP PUT Expiry: 2026-04-17 | Strike: $47.50 | Type: PUT Option Plan (premium): Entry: $3.60 Stop: $2.59 TP1: $4.68 TP2: $6.12 TP3: $8.64 🔗 https://dragonalgo.com
0 · Reply
CasinoRat
CasinoRat Mar. 20 at 4:54 PM
$CRSP
0 · Reply
CasinoRat
CasinoRat Mar. 20 at 4:08 PM
$CRSP how soon can they announce a major catalyst in the business, without the recent buyers of $600M convertibles (I.e., deep OTM call options) being credibly accused of insider trading? The answer to that question will likely determine the timing of the next major news release.
1 · Reply
Sdwg
Sdwg Mar. 20 at 2:53 PM
$CRSP offering did close on 16th, missed 8k, my bad...glta
1 · Reply
CasinoRat
CasinoRat Mar. 20 at 1:48 PM
$CRSP when quiet market exuberance gives you 1% relief after devastating losses
0 · Reply
rangerhawkeye
rangerhawkeye Mar. 20 at 1:47 PM
$CRSP really like this here
0 · Reply
Sdwg
Sdwg Mar. 20 at 1:22 PM
$CRSP still no status on offering, whats up with these clowns...probably upsizing the upsized offering....Cathy must be wetting herself about now...glta
0 · Reply
DragonAlgo
DragonAlgo Mar. 20 at 5:35 AM
🐉 $CRSP CALL — DragonAlgo® Signal Contract: CRSP CALL Expiry: 2026-03-20 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $0.10 Stop: $0.07 TP1: $0.13 TP2: $0.17 TP3: $0.24 🔗 https://dragonalgo.com
0 · Reply
MikiTrader
MikiTrader Mar. 20 at 4:25 AM
$CRSP Overweight
0 · Reply
dens214
dens214 Mar. 19 at 11:57 PM
$CRSP is there anything in the next 90 days that will stabilize or increase the stock price?
1 · Reply
Latest News on CRSP
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

Mar 11, 2026, 7:00 AM EDT - 10 days ago

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

Mar 10, 2026, 7:00 AM EDT - 11 days ago

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

Crispr Therapeutics: Very High Risk But Even Higher Potential Reward

Feb 18, 2026, 11:42 PM EST - 4 weeks ago

Crispr Therapeutics: Very High Risk But Even Higher Potential Reward

CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Feb 18, 2026, 2:14 PM EST - 4 weeks ago

CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027

Feb 17, 2026, 11:49 AM EST - 4 weeks ago

CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

Feb 13, 2026, 1:45 PM EST - 5 weeks ago

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 4:30 PM EST - 5 weeks ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Crispr Therapeutics: Patience And Opportunity Through Volatility

Jan 14, 2026, 11:30 AM EST - 2 months ago

Crispr Therapeutics: Patience And Opportunity Through Volatility

CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 3:36 PM EST - 2 months ago

CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

Jan 12, 2026, 8:36 AM EST - 2 months ago

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:30 AM EST - 2 months ago

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Crispr Therapeutics: Prospects For 2026 - Why I Believe Casgevy Is Key

Jan 2, 2026, 12:31 PM EST - 2 months ago

Crispr Therapeutics: Prospects For 2026 - Why I Believe Casgevy Is Key

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

Dec 31, 2025, 5:06 PM EST - 2 months ago

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer

Dec 22, 2025, 12:45 PM EST - 3 months ago

CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

Dec 22, 2025, 8:30 AM EST - 3 months ago

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy

Dec 4, 2025, 10:29 AM EST - 3 months ago

Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy

CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy

Nov 13, 2025, 3:43 PM EST - 4 months ago

CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 4 months ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

Nov 8, 2025, 10:03 AM EST - 4 months ago

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

Nov 8, 2025, 9:56 AM EST - 4 months ago

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

Oct 10, 2025, 8:00 AM EDT - 5 months ago

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Oct 1, 2025, 8:00 AM EDT - 6 months ago

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track

Sep 17, 2025, 4:09 PM EDT - 6 months ago

Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Sep 9, 2025, 4:00 PM EDT - 6 months ago

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

Sep 9, 2025, 2:22 PM EDT - 6 months ago

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

INCY XBI XLV

CRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 11:38 AM EDT - 6 months ago

CRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

CRISPR Therapeutics AG (CRSP) Presents at H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 9, 2025, 6:53 AM EDT - 6 months ago

CRISPR Therapeutics AG (CRSP) Presents at H.C. Wainwright 27th Annual Global Investment Conference Transcript

Crispr Therapeutics: A Winning Lottery Ticket Doesn't Replace Grand Strategy

Sep 2, 2025, 8:55 AM EDT - 7 months ago

Crispr Therapeutics: A Winning Lottery Ticket Doesn't Replace Grand Strategy

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Sep 2, 2025, 8:00 AM EDT - 7 months ago

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Crispr Therapeutics: A Speculative Buy With Promising Potential Ahead

Aug 27, 2025, 6:21 AM EDT - 7 months ago

Crispr Therapeutics: A Speculative Buy With Promising Potential Ahead

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

Aug 14, 2025, 1:02 PM EDT - 7 months ago

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

AMD ARKF ARKG ARKK ARKQ ARKW ARKX

Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025

Aug 14, 2025, 7:27 AM EDT - 7 months ago

Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 4:15 PM EDT - 8 months ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big

Jul 23, 2025, 11:03 AM EDT - 8 months ago

Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big

The Big 3: ASML, GOOGL, CRSP

Jul 15, 2025, 12:01 PM EDT - 8 months ago

The Big 3: ASML, GOOGL, CRSP

ASML GOOG GOOGL

Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)

Jul 14, 2025, 8:00 AM EDT - 8 months ago

Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

Jun 26, 2025, 7:00 AM EDT - 9 months ago

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

The Big 3: CRSP, OKLO, GME

Jun 23, 2025, 12:01 PM EDT - 9 months ago

The Big 3: CRSP, OKLO, GME

OKLO GME

Crispr Therapeutics: Betting On A One-Shot Future

Jun 13, 2025, 6:27 PM EDT - 10 months ago

Crispr Therapeutics: Betting On A One-Shot Future

CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Jun 9, 2025, 5:50 PM EDT - 10 months ago

CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)

Jun 3, 2025, 4:07 PM EDT - 10 months ago

CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)

Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines

May 9, 2025, 7:14 AM EDT - 11 months ago

Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines

CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)

May 8, 2025, 8:36 AM EDT - 11 months ago

CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)

Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course

May 7, 2025, 4:03 PM EDT - 11 months ago

Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

May 7, 2025, 2:17 PM EDT - 11 months ago

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

May 7, 2025, 8:39 AM EDT - 11 months ago

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

May 6, 2025, 4:01 PM EDT - 11 months ago

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

May 5, 2025, 4:44 AM EDT - 11 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

NTLA

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)

Apr 8, 2025, 3:29 PM EDT - 1 year ago

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

DragonAlgo
DragonAlgo Mar. 21 at 12:01 AM
🐉 $CRSP PUT — DragonAlgo® Signal Contract: CRSP PUT Expiry: 2026-04-17 | Strike: $47.50 | Type: PUT Option Plan (premium): Entry: $3.60 Stop: $2.59 TP1: $4.68 TP2: $6.12 TP3: $8.64 🔗 https://dragonalgo.com
0 · Reply
CasinoRat
CasinoRat Mar. 20 at 4:54 PM
$CRSP
0 · Reply
CasinoRat
CasinoRat Mar. 20 at 4:08 PM
$CRSP how soon can they announce a major catalyst in the business, without the recent buyers of $600M convertibles (I.e., deep OTM call options) being credibly accused of insider trading? The answer to that question will likely determine the timing of the next major news release.
1 · Reply
Sdwg
Sdwg Mar. 20 at 2:53 PM
$CRSP offering did close on 16th, missed 8k, my bad...glta
1 · Reply
CasinoRat
CasinoRat Mar. 20 at 1:48 PM
$CRSP when quiet market exuberance gives you 1% relief after devastating losses
0 · Reply
rangerhawkeye
rangerhawkeye Mar. 20 at 1:47 PM
$CRSP really like this here
0 · Reply
Sdwg
Sdwg Mar. 20 at 1:22 PM
$CRSP still no status on offering, whats up with these clowns...probably upsizing the upsized offering....Cathy must be wetting herself about now...glta
0 · Reply
DragonAlgo
DragonAlgo Mar. 20 at 5:35 AM
🐉 $CRSP CALL — DragonAlgo® Signal Contract: CRSP CALL Expiry: 2026-03-20 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $0.10 Stop: $0.07 TP1: $0.13 TP2: $0.17 TP3: $0.24 🔗 https://dragonalgo.com
0 · Reply
MikiTrader
MikiTrader Mar. 20 at 4:25 AM
$CRSP Overweight
0 · Reply
dens214
dens214 Mar. 19 at 11:57 PM
$CRSP is there anything in the next 90 days that will stabilize or increase the stock price?
1 · Reply
handmedown1
handmedown1 Mar. 19 at 10:45 PM
$CRSP im here and suffering.
0 · Reply
JasonCO
JasonCO Mar. 19 at 7:13 PM
$CRSP ready
2 · Reply
APman
APman Mar. 19 at 3:09 PM
$CRSP
1 · Reply
DragonAlgo
DragonAlgo Mar. 19 at 2:34 PM
🐉 $CRSP PUT — DragonAlgo® Signal Contract: CRSP PUT Expiry: 2026-04-17 | Strike: $60.00 | Type: PUT Option Plan (premium): Entry: $13.60 Stop: $9.79 TP1: $17.68 TP2: $23.12 TP3: $32.64 🔗 https://dragonalgo.com
0 · Reply
handmedown1
handmedown1 Mar. 19 at 12:29 PM
$CRSP we retail investors just gerting fleeced. Need activist investor with big pockets to save this turd
0 · Reply
puggzie1
puggzie1 Mar. 19 at 10:22 AM
$CRSP Vote out the CEO!
3 · Reply
dens214
dens214 Mar. 19 at 3:02 AM
$CRSP this is the second time in 60 days in 30 days actually that management has orchestrated a retreat from $60. so unless there is a management change including a board change it appears that crispr will not pass the $60 threshold.
0 · Reply
Bigfridge_sim
Bigfridge_sim Mar. 18 at 9:02 PM
$CRSP I understand the market pressures here and believe in the long term but I am tired of this management team’s performance. There needs to be change.
0 · Reply
ginobili3310
ginobili3310 Mar. 18 at 7:28 PM
$CRSP tske it to $30 already. It will feather down to fuck with you til then.
0 · Reply
burbs88
burbs88 Mar. 18 at 6:08 PM
$CRSP Would love to see this hook green today. Would be great short term signal. It just might
1 · Reply
InThePumpWeTrust
InThePumpWeTrust Mar. 18 at 2:57 PM
$CRSP cmon baby give me $45 so I can buy more
0 · Reply
Sdwg
Sdwg Mar. 18 at 2:44 PM
$CRSP must be upping the offering....stock wont go up until its closed...just my worthless opinion...glta
1 · Reply